1. Chinese authorities refer more and more to international standards such as WHO and ICH when revising regulations. China is making procedures transparent and standardized, and the administration of medical affairs by Chinese authorities is gradually becoming science based rather than based on other factors. 2. The Chinese authorities are attempting to address foreign companies' concern with new regulations. 3. Regulatory authorities are becoming more flexible by waiving additional clinical trials for the product if it is the same kind as a drug that has already been approved. 4. China is beginning to accept foreign clinical data.
